Aurinia to Participate in Jefferies London Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and twelve months ended December 31, 2024 and provided an update on recent corporate progress. Fourth Quarter 2024 Financial Results Total Revenue: For the three months ended December 31, 2024, total revenue was $59.9 million, up 33% from $45.1 million in the same period of 2023. – Net Product Sales: For the three months ended December 31, 2024, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $57.6 million, up 36% from $42.3 million in the same period of 2023. – License, Collaboration and Royalty Revenue

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27, 2025. Aurinia's management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases wi

New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and management of lupus nephritis (LN), which prioritize the urgent need to use efficacious treatments to avoid nephron loss and preserve kidney function. The guidelines call for a triple immunosuppression treatment regimen for LN, with first line use of advanced therapies like LUPKYNIS for three to five years. Importantly, the guidelin

Oppenheimer downgraded Aurinia Pharma from Outperform to Perform

Cantor Fitzgerald resumed coverage of Aurinia Pharma with a rating of Overweight and set a new price target of $25.00 from $34.00 previously

SVB Leerink reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $22.00 from $30.00 previously

4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

SCHEDULE 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

10-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry. He previously served as a director of Ardea Biosciences, Inc., Adamis Pharmaceuticals Corporation, Decipher Biosciences, Inc., La Jolla Pharmaceutical Company, Odonate Therapeutics, Inc. and Mirati Therapeutics, Inc. He currently serves as a director of Heron Therapeutics, Inc. His biography can be found here. The Company also announced that Dr. Robert

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who received less than majority support are Peter Greenleaf, Director, President and CEO; Daniel G. Billen, Ph.D., Director, Chair of the Board, Chair of the Compensation Committee, and Member of the Audit Committee; R. Hector MacKay-Dunn, J.D., K.C., Director, Chair of the Governance & Nomination Committee and Member of the Compensation Committ

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that its Board of Directors ("the Board") has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, "MKT Capital") submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board. In connection with Dr. Foster's appointment, MKT Capital has entered into a cooperation agreement with Aurinia. A complete copy of the cooperation agreement will be available on our profiles on EDGAR and SEDAR. "We are appreciative of MKT's constructive collaboration efforts. Dr. Foster brings talents which can help strengthen the Board even further

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and twelve months ended December 31, 2024 and provided an update on recent corporate progress. Fourth Quarter 2024 Financial Results Total Revenue: For the three months ended December 31, 2024, total revenue was $59.9 million, up 33% from $45.1 million in the same period of 2023. – Net Product Sales: For the three months ended December 31, 2024, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $57.6 million, up 36% from $42.3 million in the same period of 2023. – License, Collaboration and Royalty Revenue

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27, 2025. Aurinia's management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases wi

Achieved $67.8 million in total net revenue and $55.5 million in net product revenue for the third quarter of 2024, representing year-over-year growth of 24% and 36%, respectively Generated $17.0 million in cash flow from operations in the third quarter and had cash, cash equivalents, restricted cash, and investments of $348.7 million as of September 30, 2024 Anticipates a one-time restructuring charge in the fourth quarter of 2024 of $15 to $19 million and estimates post-restructuring annualized cash-based operating expense savings of more than $40 million Reiterates 2024 net product revenue guidance range of $210 to $220 million for fiscal year 2024 Webcast and conference call to

SC 13G/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

SC 13D - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

SC 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)